Form 4: BMY Director Arduini Acquires Deferred Share Units

Bristol-Myers Squibb Director Peter J. Arduini acquired 3,996.367 Deferred Share Units, increasing his beneficial ownership.

Summary

• Peter J. Arduini, a Director of Bristol-Myers Squibb Co. (BMY), acquired 3,996.367 Deferred Share Units (DSUs).
• The transaction date for this acquisition was February 1, 2026.
• Each Deferred Share Unit will convert into one share of common stock upon settlement.
• Settlement of the DSUs occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
• The price of the derivative security (Deferred Share Unit) was $55.05.
• Following this transaction, Peter J. Arduini beneficially owns a total of 70,858.084 derivative securities.
• The reported beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their stake, even through compensation, generally reflects confidence in the company's long-term value and aligns their interests with shareholders.

Positives

• The acquisition of Deferred Share Units by a director indicates continued alignment of management's interests with those of shareholders.
• An increase in beneficial ownership by a director can signal confidence in the company's future prospects.

Future Outlook

The Deferred Share Units will convert into shares of common stock upon the reporting person ceasing to be a director or at a future date specified by the reporting person, aligning future compensation with company performance.

Industry Context

StockSavvy.ai notes that director equity acquisitions, particularly through deferred compensation plans, are a common practice in the pharmaceutical industry. These transactions are often part of a director's compensation package designed to align their long-term interests with those of shareholders, reinforcing governance and commitment.

Stakeholder Impact

• Shareholders may view this as a positive indicator of director confidence and commitment to the company's long-term success, potentially reinforcing investor sentiment.

Next Steps

• The Deferred Share Units will be settled into common stock upon Peter J. Arduini ceasing to be a director or at a pre-specified future date.

Key Dates

Keywords

Bristol-Myers Squibb, BMY, Insider Transaction, Form 4, Deferred Share Units, Director Compensation, Equity Acquisition